FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:655-656 February 25, 1999 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: A 57-year-old man with a diagnosis of advanced, inoperable pancreatic cancer received palliative treatment consisting of gemcitabine (1000 mg per square meter of body-surface area given intravenously on days 1, 8, and 15) with antagonists to 5-hydroxytryptamine₃ receptors used as antiemetic prophylaxis. During the second infusion, the patient reported severe anal pruritus. The itching subsided 10 minutes after the infusion was stopped but promptly recurred after the reinstitution of treatment. When questioned, the patient said that he had also experienced itching during the first infusion, which he was embarrassed to tell anyone about in the presence of . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Dunton, C. J. (2002). Management of Treatment-Related Toxicity in Advanced Ovarian Cancer. The Oncologist 7: 11-19 [Abstract] [Full Text]